Compare
Koselugo vs. Gomekli

Koselugo (selumetinib) is a targeted therapy that works as a MEK inhibitor. It treats certain tumors caused by a genetic condition called neurofibromatosis type 1 (NF1). More specifically, it’s for adults and children 1 year and older with NF1 who have plexiform neurofibromas (PN), or small tumors around nerve tissue. Koselugo (selumetinib) comes as capsules and oral granules that are taken by mouth twice a day. But it can cause side effects like vomiting, diarrhea, and rash.

• Neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN) that can’t be removed by surgery

Children:

• Nausea
• Vomiting
• Diarrhea
• Higher creatine phosphokinase levels
• Dry skin
• Acne-like rash
• Nail infection
• Fever

Adults:

• Rash
• Acne-like rash
• Diarrhea

• Lower heart function
• Eye problems
• Diarrhea, nausea, vomiting, and mouth sores
• Skin problems
• Higher creatine phosphokinase levels
• Higher vitamin E and bleeding risk (capsules only)
• Harm to an unborn baby

Gomekli (mirdametinib) is an FDA‑approved medication for neurofibromatosis type 1 (NF1). It's used for people ages 2 years and up with NF1 who have tumors called plexiform neurofibromas (PN) that can't be fully removed with surgery. Gomekli (mirdametinib) works as a MEK inhibitor to shrink the tumors. It comes as capsules as well as tablets that can be swallowed or mixed in water. You take the medication by mouth twice a day for 21 days, then have 7 days off in a repeating 28‑day cycle. Common side effects include rash, diarrhea, and nausea.

• Neurofibromatosis type 1 (NF1) with symptomatic plexiform neurofibromas (PN) that can’t be fully removed by surgery

• Rash (82%)
• Diarrhea (57%)
• Higher creatine phosphokinase levels (57%)
• Joint, muscle, or bone pain (41%)
• Nausea (40%)
• Vomiting (39%)
• Higher triglyceride levels (37%)
• Stomach pain (32%)
• Lower hemoglobin levels (25%)

• Eye problems
• Lower heart function
• Skin reactions, including rash
• Harm to an unborn baby